{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T01:30:54Z","timestamp":1793669454851,"version":"4.5.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG-2019-ID. 23088"],"award-info":[{"award-number":["IG-2019-ID. 23088"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG-27566"],"award-info":[{"award-number":["IG-27566"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Microenvironmental signals strongly influence chronic lymphocytic leukemia (CLL) cells through the activation of distinct membrane receptors, such as B-cell receptors, and inflammatory receptors, such as Toll-like receptors (TLRs). Inflammatory pathways downstream of these receptors lead to NF-\u03baB activation, thus protecting leukemic cells from apoptosis. Dimethyl fumarate (DMF) is an anti-inflammatory and immunoregulatory drug used to treat patients with multiple sclerosis and psoriasis in which it blocks aberrant NF-\u03baB pathways and impacts the NRF2 antioxidant circuit. Our in vitro analysis demonstrated that increasing concentrations of DMF reduce ATP levels and lead to the apoptosis of CLL cells, including cell lines, splenocytes from E\u00b5-TCL1-transgenic mice, and primary leukemic cells isolated from the peripheral blood of patients. DMF showed a synergistic effect in association with BTK inhibitors in CLL cells. DMF reduced glutathione levels and activated the NRF2 pathway; gene expression analysis suggested that DMF downregulated pathways related to NFKB and inflammation. In primary leukemic cells, DMF disrupted the TLR signaling pathways induced by CpG by reducing the mRNA expression of NFKBIZ, IL6, IL10 and TNF\u03b1. Our data suggest that DMF targets a vulnerability of CLL cells linked to their inflammatory pathways, without impacting healthy donor peripheral blood mononuclear cells.<\/jats:p>","DOI":"10.1038\/s41419-024-06602-z","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:22:29Z","timestamp":1710721349000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Disrupting pro-survival and inflammatory pathways with dimethyl fumarate sensitizes chronic lymphocytic leukemia to cell death"],"prefix":"10.1038","volume":"15","author":[{"given":"Maria Elena","family":"Mantione","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Meloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilenia","family":"Sana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Bordini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Del Nero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Riba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Ranghetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Perotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3750-7342","authenticated-orcid":false,"given":"Paolo","family":"Ghia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Scarf\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7761-759X","authenticated-orcid":false,"given":"Marta","family":"Muzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"key":"6602_CR1","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41571-019-0239-8","volume":"16","author":"F Bosch","year":"2019","unstructured":"Bosch F, Dalla-Favera R. Chronic lymphocytic leukaemia: from genetics to treatment. Nat Rev Clin Oncol. 2019;16:684\u2013701.","journal-title":"Nat Rev Clin Oncol"},{"key":"6602_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nrc.2016.8","volume":"16","author":"G Fabbri","year":"2016","unstructured":"Fabbri G, Dalla-Favera R. The molecular pathogenesis of chronic lymphocytic leukaemia. Nat Rev Cancer. 2016;16:145\u201362.","journal-title":"Nat Rev Cancer"},{"key":"6602_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1169397","volume":"13","author":"A O\u2019Donnell","year":"2023","unstructured":"O\u2019Donnell A, Pepper C, Mitchell S, Pepper A. NF-kB and the CLL microenvironment. Front Oncol. 2023;13:1169397.","journal-title":"Front Oncol"},{"key":"6602_CR4","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/j.1365-2796.2008.02030.x","volume":"264","author":"P Ghia","year":"2008","unstructured":"Ghia P, Chiorazzi N, Stamatopoulos K. Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. J Intern Med. 2008;264:549\u201362.","journal-title":"J Intern Med"},{"key":"6602_CR5","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.hoc.2021.03.003","volume":"35","author":"E Vlachonikola","year":"2021","unstructured":"Vlachonikola E, Sofou E, Chatzidimitriou A, Stamatopoulos K, Agathangelidis A. The significance of B-cell receptor stereotypy in chronic lymphocytic leukemia: biological and clinical implications. Hematol Oncol Clin N Am. 2021;35:687\u2013702.","journal-title":"Hematol Oncol Clin N Am"},{"key":"6602_CR6","doi-asserted-by":"publisher","first-page":"687458","DOI":"10.3389\/fimmu.2021.687458","volume":"12","author":"IE Ahn","year":"2021","unstructured":"Ahn IE, Brown JR. Targeting Bruton\u2019s tyrosine kinase in CLL. Front Immunol. 2021;12:687458.","journal-title":"Front Immunol"},{"key":"6602_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2300696","volume":"389","author":"AR Mato","year":"2023","unstructured":"Mato AR, Woyach JA, Brown JR, Ghia P, Patel K, Eyre TA, et al. Pirtobrutinib after a Covalent BTK Inhibitor in chronic lymphocytic leukemia. N Engl J Med. 2023;389:33\u201344.","journal-title":"N Engl J Med"},{"key":"6602_CR8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1509981","volume":"374","author":"JC Byrd","year":"2016","unstructured":"Byrd JC, Harrington B, O\u2019Brien S, Jones JA, Schuh A, Devereux S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:323\u201332.","journal-title":"N Engl J Med"},{"key":"6602_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3324\/haematol.2022.281266","volume":"108","author":"SS Sk\u00e5nland","year":"2023","unstructured":"Sk\u00e5nland SS, Brown JR. PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here? Haematologica. 2023;108:9\u201321.","journal-title":"Haematologica"},{"key":"6602_CR10","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3390\/hematolrep15030047","volume":"15","author":"P Nasnas","year":"2023","unstructured":"Nasnas P, Cerchione C, Musuraca G, Martinelli G, Ferrajoli A. How I manage chronic lymphocytic leukemia. Hematol Rep. 2023;15:454\u201364.","journal-title":"Hematol Rep"},{"key":"6602_CR11","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1158\/1078-0432.CCR-12-1922","volume":"19","author":"E Fonte","year":"2013","unstructured":"Fonte E, Apollonio B, Scarf\u00f2 L, Ranghetti P, Fazi C, Ghia P, et al. In vitro sensitivity of CLL cells to fludarabine may be modulated by the stimulation of Toll-like receptors. Clinical Cancer Res. 2013;19:367\u201379.","journal-title":"Clinical Cancer Res"},{"key":"6602_CR12","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1158\/0008-5472.CAN-18-0781","volume":"79","author":"EL Dadashian","year":"2019","unstructured":"Dadashian EL, McAuley EM, Liu D, Shaffer AL, Young RM, Iyer JR, et al. TLR signaling is activated in lymph node\u2013resident CLL cells and is only partially inhibited by ibrutinib. Cancer Res. 2019;79:360\u201371.","journal-title":"Cancer Res"},{"key":"6602_CR13","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1182\/blood.2020005964","volume":"137","author":"E Kennedy","year":"2021","unstructured":"Kennedy E, Coulter E, Halliwell E, Profitos-Peleja N, Walsby E, Clark B, et al. TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target. Blood. 2021;137:3064\u201378.","journal-title":"Blood"},{"key":"6602_CR14","doi-asserted-by":"publisher","DOI":"10.15252\/msb.202110855","volume":"18","author":"PM Bruch","year":"2022","unstructured":"Bruch PM, Giles HA, Kolb C, Herbst SA, Becirovic T, Roider T, et al. Drug-microenvironment perturbations reveal resistance mechanisms and prognostic subgroups in CLL. Mol Syst Biol. 2022;18:e10855.","journal-title":"Mol Syst Biol"},{"key":"6602_CR15","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1084\/jem.20142009","volume":"212","author":"L Mansouri","year":"2015","unstructured":"Mansouri L, Sutton LA, Ljungstr\u00f6m V, Bondza S, Arng\u00e5rden L, Bhoi S, et al. Functional loss of I\u03baB\u03b5 leads to NF-\u03baB deregulation in aggressive chronic lymphocytic leukemia. J Exp Med. 2015;212:833\u201343.","journal-title":"J Exp Med"},{"key":"6602_CR16","doi-asserted-by":"publisher","first-page":"4681","DOI":"10.1182\/blood-2007-11-125278","volume":"111","author":"S Hewamana","year":"2008","unstructured":"Hewamana S, Alghazal S, Lin TT, Clement M, Jenkins C, Guzman ML, et al. The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood. 2008;111:4681\u20139.","journal-title":"Blood"},{"key":"6602_CR17","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.4049\/jimmunol.164.4.2200","volume":"164","author":"RR Furman","year":"2000","unstructured":"Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol. 2000;164:2200\u20136.","journal-title":"J Immunol"},{"key":"6602_CR18","doi-asserted-by":"publisher","first-page":"26019","DOI":"10.18632\/oncotarget.25419","volume":"9","author":"D Primo","year":"2018","unstructured":"Primo D, Scarf\u00f2 L, Xochelli A, Mattsson M, Ranghetti P, Espinosa AB, et al. A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia. Oncotarget. 2018;9:26019\u201331.","journal-title":"Oncotarget."},{"key":"6602_CR19","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1182\/blood.V95.3.999.003k10_999_1006","volume":"95","author":"T Decker","year":"2000","unstructured":"Decker T, Schneller F, Sparwasser T, Tretter T, Lipford GB, Wagner H, et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood. 2000;95:999\u20131006.","journal-title":"Blood."},{"key":"6602_CR20","doi-asserted-by":"publisher","first-page":"e0228674.","DOI":"10.1371\/journal.pone.0228674","volume":"15","author":"M Dampmann","year":"2020","unstructured":"Dampmann M, G\u00f6rgens A, M\u00f6llmann M, Murke F, D\u00fchrsen U, Giebel B, et al. CpG stimulation of chronic lymphocytic leukemia cells induces a polarized cell shape and promotes migration in vitro and in vivo. PLoS ONE.2020;15:e0228674.","journal-title":"PLoS ONE."},{"key":"6602_CR21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/sj.leu.2404417","volume":"21","author":"PG Longo","year":"2007","unstructured":"Longo PG, Laurenti L, Gobessi S, Petlickovski A, Pelosi M, Chiusolo P, et al. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia. 2007;21:110\u201320.","journal-title":"Leukemia"},{"key":"6602_CR22","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.3324\/haematol.2017.165878","volume":"102","author":"E Fonte","year":"2017","unstructured":"Fonte E, Vilia MG, Reverberi D, Sana I, Scarf\u00f2 L, Ranghetti P, et al. Toll-like receptor 9 stimulation can induce I\u03baB\u03b6 expression and IgM secretion in chronic lymphocytic leukemia cells. Haematologica. 2017;102:1901\u201312.","journal-title":"Haematologica"},{"key":"6602_CR23","doi-asserted-by":"crossref","unstructured":"Endo T, Nishio M, Enzler T, Cottam HB, Fukuda T, James DF, et al. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway - PubMed. 2007. https:\/\/pubmed.ncbi.nlm.nih.gov\/16973958\/.","DOI":"10.1182\/blood-2006-06-027755"},{"key":"6602_CR24","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2003-02-0540","volume":"103","author":"C Kern","year":"2004","unstructured":"Kern C, Cornuel JF, Billard C, Tang R, Rouillard D, Stenou V, et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood. 2004;103:679\u201388.","journal-title":"Blood"},{"key":"6602_CR25","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1038\/leu.2011.149","volume":"25","author":"C Scielzo","year":"2011","unstructured":"Scielzo C, Apollonio B, Scarf\u00f2 L, Janus A, Muzio M, Ten Hacken E, et al. The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia. Leukemia. 2011;25:1760\u20137.","journal-title":"Leukemia"},{"key":"6602_CR26","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1182\/blood-2007-04-087882","volume":"111","author":"D de Totero","year":"2008","unstructured":"de Totero D, Meazza R, Capaia M, Fabbi M, Azzarone B, Balleari E, et al. The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK\/STAT and ERK1\/2 pathways. Blood. 2008;111:517\u201324.","journal-title":"Blood."},{"key":"6602_CR27","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3324\/haematol.2010.031377","volume":"96","author":"A Schulz","year":"2011","unstructured":"Schulz A, Toedt G, Zenz T, Stilgenbauer S, Lichter P, Seiffert M. Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2. Haematologica. 2011;96:408\u201316.","journal-title":"Haematologica"},{"key":"6602_CR28","doi-asserted-by":"publisher","first-page":"7479","DOI":"10.1073\/pnas.1002890107","volume":"107","author":"RP Wu","year":"2010","unstructured":"Wu RP, Hayashi T, Cottam HB, Jin G, Yao S, Wu CCN, et al. Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2010;107:7479\u201384.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6602_CR29","doi-asserted-by":"crossref","unstructured":"Matteo P, Federico D, Emanuela M, Giulia R, Tommaso B, Alfredo G, et al. New and old horizons for an ancient drug: pharmacokinetics, pharmacodynamics, and clinical perspectives of dimethyl fumarate. Pharmaceutics. 2022;14. https:\/\/pubmed.ncbi.nlm.nih.gov\/36559226\/.","DOI":"10.3390\/pharmaceutics14122732"},{"key":"6602_CR30","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1002\/med.21567","volume":"39","author":"NEB Saidu","year":"2019","unstructured":"Saidu NEB, Kavian N, Leroy K, Jacob C, Nicco C, Batteux F, et al. Dimethyl fumarate, a two-edged drug: Current status and future directions. Med Res Rev. 2019;39:1923\u201352.","journal-title":"Med Res Rev"},{"key":"6602_CR31","doi-asserted-by":"crossref","unstructured":"Majkutewicz I. Dimethyl fumarate: a review of preclinical efficacy in models of neurodegenerative diseases. Eur J Pharmacol. 2022;926. https:\/\/pubmed.ncbi.nlm.nih.gov\/35569547\/.","DOI":"10.1016\/j.ejphar.2022.175025"},{"key":"6602_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-9-163","volume":"9","author":"P Albrecht","year":"2012","unstructured":"Albrecht P, Bouchachia I, Goebels N, Henke N, Hofstetter HH, Issberner A, et al. Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation. 2012;9:163.","journal-title":"J Neuroinflammation"},{"key":"6602_CR33","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.neuroscience.2014.11.047","volume":"286","author":"X Jing","year":"2015","unstructured":"Jing X, Shi H, Zhang C, Ren M, Han M, Wei X, et al. Dimethyl fumarate attenuates 6-OHDA-induced neurotoxicity in SH-SY5Y cells and in animal model of Parkinson\u2019s disease by enhancing Nrf2 activity. Neuroscience. 2015;286:131\u201340.","journal-title":"Neuroscience."},{"key":"6602_CR34","doi-asserted-by":"publisher","first-page":"e2350418","DOI":"10.1002\/eji.202350418","volume":"53","author":"I Sana","year":"2023","unstructured":"Sana I, Mantione ME, Meloni M, Riba M, Ranghetti P, Scarf\u00f2 L, et al. Dimethyl itaconate selectively targets inflammatory and metabolic pathways in chronic lymphocytic leukemia. Eur J Immunol. 2023;53:e2350418.","journal-title":"Eur J Immunol"},{"key":"6602_CR35","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41586-018-0052-z","volume":"556","author":"M Bambouskova","year":"2018","unstructured":"Bambouskova M, Gorvel L, Lampropoulou V, Sergushichev A, Loginicheva E, Johnson K, et al. Electrophilic properties of itaconate and derivatives regulate the I\u03baB\u03b6-ATF3 inflammatory axis. Nature. 2018;556:501\u20134.","journal-title":"Nature"},{"key":"6602_CR36","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.4049\/jimmunol.1801627","volume":"202","author":"BW Zaro","year":"2019","unstructured":"Zaro BW, Vinogradova EV, Lazar DC, Blewett MM, Suciu RM, Takaya J, et al. Dimethyl fumarate disrupts human innate immune signaling by targeting the IRAK4-MyD88 complex. J Immunol. 2019;202:2737\u201346.","journal-title":"J Immunol"},{"key":"6602_CR37","doi-asserted-by":"crossref","unstructured":"Selman M, Ou P, Rousso C, Bergeron A, Krishnan R, Pikor L, et al. Dimethyl fumarate potentiates oncolytic virotherapy through NF-\u03baB inhibition. Science translational medicine. 2018;10. https:\/\/pubmed.ncbi.nlm.nih.gov\/29367345\/.","DOI":"10.1126\/scitranslmed.aao1613"},{"key":"6602_CR38","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1126\/science.aan4665","volume":"360","author":"MD Kornberg","year":"2018","unstructured":"Kornberg MD, Bhargava P, Kim PM, Putluri V, Snowman AM, Putluri N, et al. Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity. Science. 2018;360:449\u201353.","journal-title":"Science"},{"key":"6602_CR39","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.4049\/jimmunol.1601532","volume":"198","author":"Q Wu","year":"2017","unstructured":"Wu Q, Wang Q, Mao G, Dowling CA, Lundy SK, Mao-Draayer Y. Dimethyl fumarate selectively reduces memory T cells and shifts the balance between Th1\/Th17 and Th2 in multiple sclerosis patients. J Immunol. 2017;198:3069\u201380.","journal-title":"J Immunol"},{"key":"6602_CR40","doi-asserted-by":"publisher","first-page":"691","DOI":"10.4049\/jimmunol.1601649","volume":"198","author":"R Li","year":"2017","unstructured":"Li R, Rezk A, Ghadiri M, Luessi F, Zipp F, Li H, et al. Dimethyl fumarate treatment mediates an anti-inflammatory shift in B cell subsets of patients with multiple sclerosis. J Immunol. 2017;198:691\u20138.","journal-title":"J Immunol"},{"key":"6602_CR41","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1182\/blood-2016-01-694117","volume":"128","author":"JP Nicolay","year":"2016","unstructured":"Nicolay JP, M\u00fcller-Decker K, Schroeder A, Brechmann M, M\u00f6bs M, G\u00e9raud C, et al. Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-\u03baB. Blood. 2016;128:805\u201315.","journal-title":"Blood"},{"key":"6602_CR42","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-16-1446","volume":"23","author":"V Patel","year":"2017","unstructured":"Patel V, Balakrishnan K, Bibikova E, Ayres M, Keating MJ, Wierda WG, et al. Comparison of acalabrutinib, a selective bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells. Clin Cancer Res. 2017;23:3734\u201343.","journal-title":"Clin Cancer Res"},{"key":"6602_CR43","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 2022;50:W739\u201343.","journal-title":"Nucleic Acids Res"},{"key":"6602_CR44","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1038\/s41375-020-0846-5","volume":"34","author":"M Lukas","year":"2020","unstructured":"Lukas M, Velten B, Sellner L, Tomska K, H\u00fcellein J, Walther T, et al. Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies. Leukemia. 2020;34:2934\u201350.","journal-title":"Leukemia."},{"key":"6602_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1264842","volume":"14","author":"G Bresciani","year":"2023","unstructured":"Bresciani G, Manai F, Davinelli S, Tucci P, Saso L, Amadio M. Novel potential pharmacological applications of dimethyl fumarate-an overview and update. Front Pharmacol. 2023;14:1264842.","journal-title":"Front Pharmacol"},{"key":"6602_CR46","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1182\/blood.2020009404","volume":"138","author":"A Schmitt","year":"2021","unstructured":"Schmitt A, Xu W, Bucher P, Grimm M, Konantz M, Horn H, et al. Dimethyl fumarate induces ferroptosis and impairs NF-\u03baB\/STAT3 signaling in DLBCL. Blood. 2021;138:871\u201384.","journal-title":"Blood"},{"key":"6602_CR47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jneuroim.2016.08.006","volume":"299","author":"H Peng","year":"2016","unstructured":"Peng H, Li H, Sheehy A, Cullen P, Allaire N, Scannevin RH. Dimethyl fumarate alters microglia phenotype and protects neurons against proinflammatory toxic microenvironments. J Neuroimmunol. 2016;299:35\u201344.","journal-title":"J Neuroimmunol"},{"key":"6602_CR48","doi-asserted-by":"crossref","unstructured":"Mills EA, Ogrodnik MA, Plave A, Mao-Draayer Y. Emerging understanding of the mechanism of action for dimethyl fumarate in the treatment of multiple sclerosis. Front Neurol. 2018;9. https:\/\/pubmed.ncbi.nlm.nih.gov\/29410647\/.","DOI":"10.3389\/fneur.2018.00005"},{"key":"6602_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10:1523.","journal-title":"Nat Commun"},{"key":"6602_CR50","doi-asserted-by":"crossref","unstructured":"Dello Russo C, Scott KA, Pirmohamed M Dimethyl fumarate induced lymphopenia in multiple sclerosis: a review of the literature. Pharmacol Ther. 2021;219. https:\/\/pubmed.ncbi.nlm.nih.gov\/33091427\/.","DOI":"10.1016\/j.pharmthera.2020.107710"},{"key":"6602_CR51","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1038\/s41418-020-0496-1","volume":"27","author":"E Sanchez-Lopez","year":"2020","unstructured":"Sanchez-Lopez E, Ghia EM, Antonucci L, Sharma N, Rassenti LZ, Xu J, et al. NF-\u03baB-p62-NRF2 survival signaling is associated with high ROR1 expression in chronic lymphocytic leukemia. Cell Death Differ. 2020;27:2206\u201316.","journal-title":"Cell Death Differ"},{"key":"6602_CR52","doi-asserted-by":"crossref","unstructured":"Kalyanaraman B. NAC, NAC, Knockin\u2019 on Heaven\u2019s door: Interpreting the mechanism of action of N-acetylcysteine in tumor and immune cells - PubMed. 2022. https:\/\/pubmed.ncbi.nlm.nih.gov\/36242913\/.","DOI":"10.1016\/j.redox.2022.102497"},{"key":"6602_CR53","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/jid.2008.197","volume":"129","author":"M Rostami-Yazdi","year":"2009","unstructured":"Rostami-Yazdi M, Clement B, Schmidt TJ, Schinor D, Mrowietz U. Detection of metabolites of fumaric acid esters in human urine: implications for their mode of action. J Investig Dermatol. 2009;129:231\u20134.","journal-title":"J Investig Dermatol"},{"key":"6602_CR54","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00403-013-1332-y","volume":"305","author":"S Dibbert","year":"2013","unstructured":"Dibbert S, Clement B, Skak-Nielsen T, Mrowietz U, Rostami-Yazdi M. Detection of fumarate-glutathione adducts in the portal vein blood of rats: evidence for rapid dimethylfumarate metabolism. Arch Dermatol Res. 2013;305:447\u201351.","journal-title":"Arch Dermatol Res"},{"key":"6602_CR55","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.biopha.2014.09.009","volume":"68","author":"M Tsubaki","year":"2014","unstructured":"Tsubaki M, Ogawa N, Takeda T, Sakamoto K, Shimaoka H, Fujita A, et al. Dimethyl fumarate induces apoptosis of hematopoietic tumor cells via inhibition of NF-\u03baB nuclear translocation and down-regulation of Bcl-xL and XIAP. Biomed Pharmacother. 2014;68:999\u20131005.","journal-title":"Biomed Pharmacother"},{"key":"6602_CR56","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/S0959-8049(21)00666-3","volume":"156","author":"JP Nicolay","year":"2021","unstructured":"Nicolay JP, Albrecht JD, Assaf C, Dippel E, Stadler R, Wehkamp U, et al. Dimethyl fumarate (DMF) therapy in CTCL: results from a clinical phase II study. Eur J Cancer. 2021;156:S21\u20132.","journal-title":"Eur J Cancer"},{"key":"6602_CR57","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jsbmb.2018.11.017","volume":"188","author":"M Nachliely","year":"2019","unstructured":"Nachliely M, Trachtenberg A, Khalfin B, Nalbandyan K, Cohen-Lahav M, Yasuda K, et al. Dimethyl fumarate and vitamin D derivatives cooperatively enhance VDR and Nrf2 signaling in differentiating AML cells in vitro and inhibit leukemia progression in a xenograft mouse model. J Steroid Biochem Mol Biol. 2019;188:8\u201316.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"6602_CR58","doi-asserted-by":"publisher","first-page":"11888","DOI":"10.1158\/0008-5472.CAN-06-2397","volume":"66","author":"R Loewe","year":"2006","unstructured":"Loewe R, Valero T, Kremling S, Pratscher B, Kunstfeld R, Pehamberger H, et al. Dimethylfumarate impairs melanoma growth and metastasis. Cancer Res. 2006;66:11888\u201396.","journal-title":"Cancer Res"},{"key":"6602_CR59","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.cellbi.2009.06.027","volume":"33","author":"Y Yamazoe","year":"2009","unstructured":"Yamazoe Y, Tsubaki M, Matsuoka H, Satou T, Itoh T, Kusunoki T, et al. Dimethylfumarate inhibits tumor cell invasion and metastasis by suppressing the expression and activities of matrix metalloproteinases in melanoma cells. Cell Biol Int. 2009;33:1087\u201394.","journal-title":"Cell Biol Int"},{"key":"6602_CR60","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jdermsci.2020.07.004","volume":"99","author":"T Takeda","year":"2020","unstructured":"Takeda T, Tsubaki M, Asano R, Itoh T, Imano M, Satou T, et al. Dimethyl fumarate suppresses metastasis and growth of melanoma cells by inhibiting the nuclear translocation of NF-\u03baB. J Dermatol Sci. 2020;99:168\u201376.","journal-title":"J Dermatol Sci"},{"key":"6602_CR61","doi-asserted-by":"crossref","unstructured":"Tsurushima K, Tsubaki M, Takeda T, Matsuda T, Kimura A, Takefuji H, et al. Dimethyl fumarate induces apoptosis via inhibition of NF-\u03baB and enhances the effect of paclitaxel and adriamycin in human TNBC cells. Int J Mol Sci. 2022;23. https:\/\/pubmed.ncbi.nlm.nih.gov\/35955813\/.","DOI":"10.3390\/ijms23158681"},{"key":"6602_CR62","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1074\/jbc.M115.679704","volume":"291","author":"I Kastrati","year":"2016","unstructured":"Kastrati I, Siklos MI, Calderon-Gierszal EL, El-Shennawy L, Georgieva G, Thayer EN, et al. Dimethyl fumarate inhibits the nuclear factor \u03baB pathway in breast cancer cells by covalent modification of p65 protein. J Biol Chem. 2016;291:3639\u201347.","journal-title":"J Biol Chem"},{"key":"6602_CR63","doi-asserted-by":"publisher","first-page":"8192","DOI":"10.3390\/ijms23158192","volume":"23","author":"T Rupp","year":"2022","unstructured":"Rupp T, Debasly S, Genest L, Froget G, Castagn\u00e9 V. Therapeutic potential of fingolimod and dimethyl fumarate in non-small cell lung cancer preclinical models. Int J Mol Sci. 2022;23:8192.","journal-title":"Int J Mol Sci"},{"key":"6602_CR64","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745\u201360.","journal-title":"Blood"},{"key":"6602_CR65","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.","journal-title":"Nucleic Acids Res"},{"key":"6602_CR66","doi-asserted-by":"publisher","first-page":"W147","DOI":"10.1093\/nar\/gkw419","volume":"44","author":"S Babicki","year":"2016","unstructured":"Babicki S, Arndt D, Marcu A, Liang Y, Grant JR, Maciejewski A, et al. Heatmapper: web-enabled heat mapping for all. Nucleic Acids Res. 2016;44:W147\u201353.","journal-title":"Nucleic Acids Res"},{"key":"6602_CR67","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","volume":"41","author":"F Faul","year":"2009","unstructured":"Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41:1149\u201360.","journal-title":"Behav Res Methods"},{"key":"6602_CR68","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3758\/BF03193146","volume":"39","author":"F Faul","year":"2007","unstructured":"Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175\u201391.","journal-title":"Behav Res Methods"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06602-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06602-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06602-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T01:02:43Z","timestamp":1710723763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06602-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":68,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["6602"],"URL":"https:\/\/doi.org\/10.1038\/s41419-024-06602-z","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]},"assertion":[{"value":"23 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LS received honoraria from AbbVie, AstraZeneca, BeiGene, Janssen, Lilly, OctaPharma. PG received honoraria from AbbVie, AstraZeneca, ArQule\/MSD, Celgene\/Juno\/BMS, Janssen, Lilly\/loxo, Roche; Research support from AbbVie, AstraZeneca, Janssen. All other authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"224"}}